12:02 PM EST, 11/24/2025 (MT Newswires) -- The European stock markets closed mostly higher in Monday trading as the Stoxx Europe rose 0.36%, Germany's DAX advanced 0.75%, the FTSE 100 gained 0.15%, the Swiss Market Index increased 0.42%, while France's CAC was closed 0.29% lower.

The business sentiment in Germany has worsened, according to the ifo Business Climate Index, which fell to 88.1 points in November from 88.4 points in October. The economic research organization attributed the decline to more pessimistic expectations and said it doubts there will be a "swift recovery" for the German economy.

The ifo said the index in the manufacturing sector fell, while expectations took a significant hit as companies have become more skeptical about the coming months, with order books declining slightly.

In Switzerland, total employment excluding agriculture edged 0.1% higher in Q3 to approximately 5.5 million, compared with a year earlier, according to the Swiss Federal Statistical Office. The FSO said companies reported 10.5% fewer vacancies than the previous year, citing difficulties recruiting skilled workers.

And in corporate news, BHP Group said Monday it is no longer contemplating a combination with Anglo American following preliminary talks discussions with Anglo's board.

"Whilst BHP continues to believe that a combination with Anglo American would have had strong strategic merits and created significant value for all stakeholders, BHP is confident in the highly compelling potential of its own organic growth strategy," the company said.

Shares of the British mining company were little changed in London.

Novo Nordisk said that its weight-loss drug semaglutide failed to meet its primary endpoint of reducing Alzheimer's progression in two phase 3 trials enrolling a total of 3,808 adults. The drug failed to show a statistically significant reduction in disease progression compared with a placebo combined with standard of care, the company said.

Treatment with semaglutide showed improvement in some related biomarkers but did not slow the advancement of the disease, the company said.

Shares of the Danish pharmaceutical company fell nearly 6% in Copenhagen.

Alvotech said Monday the European Commission has approved its denosumab biosimilar medicine used to treat osteoporosis and help prevent serious bone problems in some forms of cancer.

In Europe, Alvotech will supply the medicine to partners Stada and Dr Reddy's, which will sell it under the brands Kefdensis, Zvogra, Acvybra, and Xbonzy, while Prolia and Xgeva remain registered trademarks of Amgen, the company said.

Shares of Alvotech closed nearly 4% higher in Stockholm.

BP continued to search for the source of a leak on its Olympic Pipeline near Everett, Washington, on Sunday, nearly two weeks after the breach was detected, news outlets reported. The leak has disrupted fuel supplies to Seattle-Tacoma International Airport ahead of the Thanksgiving holiday travel period, news outlets reported.

BP did not immediately reply to MT Newswires' request for comment.

Shares of the oil and gas giant were 0.1% higher in London.